MiRXES Pte Ltd, (HQ: Singapore) has launched the world’s first large-scale clinical research Project,  CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE aims to develop a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.

Project CADENCE is focused to discover and validate novel combinations of blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers for this purpose.

Witnessed by Guest-of-Honor, Mr. Ong Ye Kung, Minister for Health, MiRXES signed this MOU together with the National Cancer Centre Singapore, Nanyang Technological University, Singapore, (NTU Singapore), National University Hospital, Singapore General Hospital, Singapore Translational Cancer Consortium, Tan Tock Seng Hospital and Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine).

This MOU represents a new public-private partnership where Project CADENCE, aims to address the rising cancer incidence rate and economic impact in Singapore and globally through early detection.

The global efforts are driven by Singapore’s institutes of higher learning (IHLs) and public healthcare institutions (PHIs) represented by all three healthcare clusters and powered by MiRXES.

Project CADENCE will receive an investment of an estimated S$50 million and more by MiRXES over a three-year period, with substantial in-kind contributions from the IHLs and PHIs. The project will also see the creation of more than 80 new positions in research, manufacturing, and data science over the next three years.

At Project CADENCE we leverage our proprietary technologies, a decade-long RNA clinical test development experience, and Singapore’s strong clinical research and translation infrastructure, to develop a novel blood test that offers physicians and at-risk individuals the earliest possible signs of multiple solid cancers through a holistic analysis of miRNA and DNA biomarkers. MiRXES continue to accelerate the development and commercialization of miRNA-powered in vitro diagnostic (IVD) blood tests in oncology as well as pulmonary and cardiovascular disease areas” says Dr. Zhou Lihan, Co-founder and CEO of MiRXES.